Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Pioglitazone, rosiglitazone face up to MI, HF risk analyses

    • 8 Accesses

    This is a preview of subscription content, log in to check access.

    REFERENCE

    1. 1.

      Lincoff AM, Wolski K, Nicholls SJ, Nissen SE.Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA: the Journal of the American Medical Association 298: 1180-1188, No. 10, 12 Sep 2007

    2. 2.

      Singh S, Loke YK, Furberg CD.Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA: the Journal of the American Medical Association 298: 1189-1195, No. 10, 12 Sep 2007

    3. 3.

      Takeda Pharmaceuticals North America Inc.Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association. Media Release: 11 Sep 2007. Available from: URL: http://www.tpna.com

    4. 4.

      GlaxoSmithKline.GlaxoSmithKline Responds to JAMA Articles. Media Release: 11 Sep 2007. Available from: URL: http://www.gsk.com

    5. 5.

      Solomon DH, Winkelmayer WC.Cardiovascular risk and the thiazolidinediones: deja vu all over again? JAMA: the Journal of the American Medical Association 298: 1216-1218, No. 10, 12 Sep 2007

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Pioglitazone, rosiglitazone face up to MI, HF risk analyses. React. Wkly. 1170, 5 (2007). https://doi.org/10.2165/00128415-200711700-00010

    Download citation

    Keywords

    • Heart Failure
    • Myocardial Infarction
    • Rosiglitazone
    • Pioglitazone
    • Actos